Coronary CTO PCI Using Antegrade Wiring Strategy With a First-choice Gladius Guidewire (Gladius First)

Sponsor
Institute of Cardiology, Warsaw, Poland (Other)
Overall Status
Recruiting
CT.gov ID
NCT04691778
Collaborator
(none)
70
1
2
15.7
4.4

Study Details

Study Description

Brief Summary

The Gladius First trial is designed as a single-centre, open, prospective, randomized clinical trial aimed to assess the efficiency and safety of coronary chronic total occlusion (CTO) percutaneous coronary intervention (PCI) using the antegrade wiring strategy with a first-choice intermediate Gladius guidewire. To this end, consecutive patients referred to CTO PCI with intended primary antegrade wire escalation strategy, will be randomized in a 1:1 fashion to antegrade wiring starting with the Gladius guidewire or antegrade wiring using the standard guidewire escalation strategy.

Condition or Disease Intervention/Treatment Phase
  • Procedure: CTO PCI with the first-choice Gladius guidewire
  • Procedure: CTO PCI without the first-choice Gladius guidewire
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
70 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Coronary Chronic Total Occlusion Percutaneous Coronary Intervention Using Antegrade Wiring Strategy With a First-choice Gladius Guidewire: a Randomized Clinical Study (Gladius First Trial)
Actual Study Start Date :
Dec 8, 2020
Anticipated Primary Completion Date :
Mar 31, 2022
Anticipated Study Completion Date :
Apr 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: CTO PCI using antegrade wiring strategy starting with the Gladius guidewire

Study subjects will undergo CTO PCI with primary antegrade wiring strategy starting with the Gladius guidewire. In case of failed CTO crossing with the Gladius wire, the decision on continuing antegrade wire escalation with a different wire or switching to a different CTO PCI strategy will be left to the discretion of the operator.

Procedure: CTO PCI with the first-choice Gladius guidewire
CTO PCI using antegrade wiring strategy with the first-choice Gladius guidewire

Other: CTO PCI using standard antegrade wire escalation strategy

Control subjects will undergo CTO PCI using standard antegrade wiring strategy starting with the lower/intermediate penetration force guidewires and, if necessary, escalating up to high gram-force guidewires, but without the use of first-choice Gladius guidewire.

Procedure: CTO PCI without the first-choice Gladius guidewire
CTO PCI using standard antegrade wire escalation strategy

Outcome Measures

Primary Outcome Measures

  1. time-efficiency of antegrade wiring strategy [during procedure (intraprocedural)]

    time-efficiency of antegrade wiring strategy defined as the time from advancement of the first wire into the proximal cap to either the time of successful antegrade wiring through the lesion or the time of cessation of antegrade wiring and changing CTO PCI strategy according to the hybrid algorithm

Secondary Outcome Measures

  1. time-efficiency of successful antegrade wiring strategy [during procedure (intraprocedural)]

    time-efficiency of successful antegrade wiring strategy defined as the time from advancement of the first wire into the proximal cap to the time of successful antegrade wiring through the lesion

  2. time-efficiency of successful antegrade approach [during procedure (intraprocedural)]

    time-efficiency of successful antegrade approach defined as the time from advancement of the first wire into the proximal cap to either the time of successful antegrade wiring through the lesion or successful antegrade dissection and re-entry strategy

  3. time-efficiency of antegrade approach [during procedure (intraprocedural)]

    time-efficiency of antegrade approach defined as the time from advancement of the first wire into the proximal cap to either the time of successful antegrade wiring or antegrade dissection and re-entry strategy or the time of failed antegrade approach and changing CTO PCI strategy according to the hybrid algorithm

  4. time-efficiency of successful CTO recanalization using any technique [during procedure (intraprocedural)]

    time-efficiency defined as the time from advancement of the first wire into the proximal cap to the time of successful CTO recanalization using any technique (including antegrade and retrograde strategies)

  5. total procedural time [during procedure (intraprocedural)]

    total procedural time defined as the time from getting arterial access to the time of removal of the arterial sheaths

  6. successful guidewire crossing through CTO using antegrade wiring strategy [during procedure (intraprocedural)]

    successful guidewire crossing through CTO using antegrade wiring strategy

  7. successful guidewire crossing through CTO with restoration of flow using antegrade wiring strategy [during procedure (intraprocedural)]

    successful guidewire crossing through CTO with restoration of flow (<50% residual stenosis and TIMI flow grade 3) using antegrade wiring strategy

  8. successful guidewire crossing through CTO using antegrade approach (including antegrade wiring and antegrade dissection and re-entry strategies) [during procedure (intraprocedural)]

    successful guidewire crossing through CTO using antegrade approach (including antegrade wiring and antegrade dissection and re-entry strategies)

  9. successful guidewire crossing through CTO with restoration of flow using antegrade approach (including antegrade wiring and antegrade dissection and re-entry strategies) [during procedure (intraprocedural)]

    successful guidewire crossing through CTO with restoration of flow (<50% residual stenosis and TIMI flow grade 3) using antegrade approach (including antegrade wiring and antegrade dissection and re-entry strategies)

  10. final procedural success defined as successful guidewire crossing through CTO with restoration of flow [during procedure (intraprocedural)]

    final procedural success defined as successful guidewire crossing through CTO with restoration of flow (<50% residual stenosis and TIMI flow grade 3)

  11. contrast volume related to successful guidewire crossing through CTO using antegrade wiring strategy [during procedure (intraprocedural)]

    contrast volume related to successful guidewire crossing through CTO using antegrade wiring strategy

  12. total contrast volume [during procedure (intraprocedural)]

    total contrast volume

  13. radiation dose related to successful guidewire crossing through CTO using antegrade wiring strategy [during procedure (intraprocedural)]

    radiation dose related to successful guidewire crossing through CTO using antegrade wiring strategy

  14. total radiation dose [during procedure (intraprocedural)]

    total radiation dose

  15. incidence of periprocedural complications [during hospitalization (assessed up to 30 days)]

    incidence of periprocedural complications defined as: coronary perforation, tamponade, life-threatening arrhythmia requiring treatment, transient ischemic attack, stroke, myocardial infarction, urgent cardiac surgery, death

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • delivery of an informed consent and compliance with study protocol

  • CTO of a major coronary artery with at least intermediate difficulty score (J-CTO ≥1) as assessed by invasive angiography

  • referral to clinically indicated CTO PCI with intended primary antegrade wiring strategy

Exclusion Criteria:
  • in-stent CTO

  • unstable angina and/or myocardial infarction

  • prior myocardial infarction within 4 weeks before study enrolment

  • CTO of a major coronary artery with an easy difficulty score (J-CTO 0) as assessed by invasive coronary angiography

  • lack of valid antegrade wire escalation strategy as assessed by 2 independent CTO PCI operators

  • chronic kidney disease (defined as eGFR ≤30 ml/min/m2)

  • contraindication to antiplatelet therapy and/or heparin

  • severe inflammatory disease

  • positive pregnancy test or breast-feeding

Contacts and Locations

Locations

Site City State Country Postal Code
1 National Institute of Cardiology Warsaw Poland 04-628

Sponsors and Collaborators

  • Institute of Cardiology, Warsaw, Poland

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Institute of Cardiology, Warsaw, Poland
ClinicalTrials.gov Identifier:
NCT04691778
Other Study ID Numbers:
  • 2.59/III/20
First Posted:
Dec 31, 2020
Last Update Posted:
Dec 31, 2020
Last Verified:
Dec 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 31, 2020